Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — Investor Presentation (September 2022)

18 slides from Vivoryon Therapeutics's investor presentation, September 2022

  1. Slide 1: Tackling AD at the roots: early intervention to address multiple hallmarks of AD

    Tackling AD at the roots: early intervention to address multiple hallmarks of AD |Vivoryon Therapeutics N.V. - September 2022

  2. Slide 2: Important Notice and Disclaimer

    IMPORTANT NOTICE AND DISCLAIMER IMPORTANT: YOU MUST READ THE BELOW BEFORE READING THIS DOCUMENT This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to se

  3. Slide 3: Investment Highlights

    VIVORYON THERAPEUTICS Investment Highlights Enzyme inhibition for targeted intervention: Modulating the activity of proteins altered in disease settings Lead product candidate varoglutamstat in AD: Phase 2a evidence of disease-modifying activity and FDA Fast Track designation: Statistically signific

  4. Slide 4: Experienced Leadership

    EXPERIENCED LEADERSHIP Seasoned Biopharma Experts Covering All Relevant Aspects of Drug Development MANAGEMENT NON-EXECUTIVE DIRECTORS Erich Platzer, MD Ulrich Dauer, PhD Chairman Chief Executive Officer, Executive Director Dinnies Johannes von der Osten, PhD Vice Chairman Charlotte Lohmann Michael

  5. Slide 5: Diverse Pipeline Addressing Severe Indications

    DIVERSE PIPELINE ADDRESSING SEVERE INDICATIONS Program Approach Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Varoglutamstat SMI (PQ912) QPCT/L VIVIAD - Ph2b in EU Varoglutamstat SMI (PQ912) QPCT/L VIVA-MIND - Ph2a/b in US Varoglutamstat SMI (SIM0408, PQ912) QPCT/L CTA approval in China mA

  6. Slide 6: Alzheimer's Disease: The Burden and a Path Forward

    ALZHEIMER’S DISEASE THE BURDEN A PATH FORWARD ~30 million people suffering from AD VVY discovered QPCT-mediated formation of a neurotoxic Abeta variant, worldwide, number expected to double by N3pE amyloid (pGlu-Abeta), as driver of AD pathology1,2 2050, with ~12.7 million in the US alone VVY is dev

  7. Slide 7: Drug Development in Alzheimer's Disease

    DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE THE CHALLENGE Low success rate and long development phase delay new treatments and discourage investment in AD drug development Studies across drug development programs have identified important strategies for decreasing the risk and increasing the likelihood

  8. Slide 8: Targeting QPCT/L in AD

    TARGETING QPCT/L IN AD Validated Target for Intervention Upstream of Pathological Processes ROLE OF QPCT/L IN AD PATHOLOGY NEUROTOXIC N3PE DRIVES AD PATHOLOGY Increased activity of glutaminyl cyclase (QPCT) is CCL2 Abeta associated with AD pathology in humans1 upregulated in AD Varoglutamstat QPCT c

  9. Slide 9: Targeting Multiple Pathogenetic Hallmarks of AD

    TARGETING MULTIPLE PATHOGENETIC HALLMARKS OF AD Varoglutamstat Inhibits Formation of Toxic Abeta Species Upstream of Other Approaches ROLE OF QPCT/L IN AD PATHOLOGY VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS Increased activity of glutaminyl cyclase (QPCT) is CCL2 Abeta associated with AD pathology

  10. Slide 10: Varoglutamstat: Potential to Alter the Course of AD

    VAROGLUTAMSTAT: POTENTIAL TO ALTER THE COURSE OF AD Translating in vivo Evidence for Relevance of QPCT Inhibition into Human AD Abeta Pathology QPCT is essential for N3pE amyloid formation in vivo1 Dose-dependent reduction of QPCT 5XFAD mice, QPCT ko and tg QPCT/ N3pE activity in CSF & serum (Ph1 +

  11. Slide 11: Clinical Development Strategy

    CLINICAL DEVELOPMENT STRATEGY Clear Path To Potential Regulatory Approval Extensive Phase 1 and Phase 2 trials Pivotal study or Phase 2b VIVIAD accelerated approval Assessment of safety, tolerability and FDA Fast Track designation efficacy in 250 Patients MCI and mild AD granted in 2021 Two possible

  12. Slide 12: Summary of Key Phase 2a Results

    SAPHIR– GUIDING PHASE 2B TRIAL DESIGN COGNITION INFORMED TRIAL DESIGN OF EU PHASE 2B Statistically significant changes from baseline in a SUMMARY OF KEY PHASE 2A RESULTS working memory parameter within 3 months (One Back DOSING Test) CCL2 DLT reached at 800 mg BID; reported AEs mostly mild to Notabl

  13. Slide 13: Multiple Avenues to Value Generation

    MULTIPLE AVENUES TO VALUE GENERATION Diverse Pipeline of Oral Small Molecule Inhibitors to Address Exceptionally High Medical Need ALZHEIMER‘S DISEASE INFLAMMATION/NASH Small molecule oral QPCT/L inhibitors with good Small molecule QPCTL inhibitors to modulate the blood-brain barrier penetration CCL

  14. Slide 14: QPCTL Inhibition in Cancer

    QPCTL INHIBITION IN CANCER Opportunity to Develop Oral Small Molecule Inhibitors in Immuno-Oncology BACKGROUND OPPORTUNITY Large unmet medical need remains to effectively and safely treat cancer Novel orally administered small molecule approach with differentiated mode patients of action: no antigen

  15. Slide 15: QPCTL Inhibition in Inflammation/NASH

    QPCTL INHIBITION IN INFLAMMATION/NASH Opportunity to Develop Oral Small Molecule Inhibitors in Inflammatory Kidney and Liver Diseases BACKGROUND OPPORTUNITY Non-alcoholic fatty liver disease (NAFLD) is a chronic hepatic Novel orally available compounds with a differentiated mode of disorder characte

  16. Slide 16: Meprin Inhibition in AKI/CKD

    MEPRIN INHIBITION IN AKI/CKD Opportunity to Develop Oral Small Molecule Inhibitors In Fibrosis and Kidney Diseases BACKGROUND OPPORTUNITY The estimated incidence rate of acute kidney injury (AKI) during Novel orally available picomolar small molecule inhibitors targeting hospitalization in the US is

  17. Slide 17: Summary

    VIVORYON THERAPEUTICS Summary PRESENT FOCUS FUTURE OPPORTUNITIES UPCOMING CATALYSTS Differentiated upstream Regional partnership with approach targeting all three Simcere: VIVIAD European Phase 2b: major hallmarks of AD Development opportunities for Final readout H2/2023 Allows intervention very ear

  18. Slide 18: Vivoryon Therapeutics N.V. Contact

    Vivoryon Therapeutics N.V. Munich Franz-Josef-Delonge-Str. 5 81249 München Germany Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com

Vivoryon Therapeutics — Investor Presentation (September 2022) on 6ix